Dienstag, 30. April 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Rekrutierend

NCT-Nummer:
NCT05608291

Studienbeginn:
Januar 2023

Letztes Update:
22.04.2024

Wirkstoff:
Fianlimab, Cemiplimab, Pembrolizumab, Placebo

Indikation (Clinical Trials):
Melanoma

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
Phase 3

Sponsor:
Regeneron Pharmaceuticals

Collaborator:
-

Studienleiter

Clinical Trial Management
Study Director
Regeneron Pharmaceuticals

Kontakt

Studienlocations
(3 von 196)

University Medical Center Mannheim
68167 Mannheim
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
University Hospital Tuebingen
72076 Tubingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Hautklinik Universitatsklinikum Erlangen
91054 Erlangen
(Bayern)
GermanyRekrutierend» Google-Maps
LMU Klinikum Munchen, Pharmacy
80337 Munchen
(Bayern)
GermanyRekrutierend» Google-Maps
Klinikum Darmstadt GmbH
64283 Darmstadt
(Hessen)
GermanyRekrutierend» Google-Maps
Universitatsmedizin Gottingen
37075 Gottingen
(Niedersachsen)
GermanyRekrutierend» Google-Maps
Helios Kliniken Schwerin GmbH, Apotheke
19055 Schwerin
(Mecklenburg-Vorpommern)
GermanyRekrutierend» Google-Maps
Universitaetstklinikum Muenster Central Study Coordination for innovative Dermatology (ZID)
48149 Muenster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Hohenzollernapotheke
48157 Muenster
(Nordrhein-Westfalen)
GermanySchwebend» Google-Maps
Klinikum der Stadt Ludwigshafen am Rhein
67063 Ludwigshafen
(Rheinland-Pfalz)
GermanyRekrutierend» Google-Maps
Harzklinikum Dorothea Christiane Erxleben GmbH, Zentrale Krankenhausapotheke
06484 Quedlinburg
(Sachsen-Anhalt)
GermanyRekrutierend» Google-Maps
Universitatsklinikum Carl Gustav Carus Dresden, Klinik Apotheke - building 60
01307 Dresden
(Sachsen)
GermanyRekrutierend» Google-Maps
UKSH-Campus Kiel
24105 Kiel
(Schleswig-Holstein)
GermanyRekrutierend» Google-Maps
Campus Virchow Klinikum, Apotheke Zytostatika Studien, Charite - Universitatsmedizin Berlin,
10117 Berlin
(Berlin)
GermanyRekrutierend» Google-Maps
Katholisches Klinikum Bochum -Zentral Apotheke
44791 Bochum
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Klinikum Bremen-Ost - Studienambulanz Dermatologie
28325 Bremen
GermanyRekrutierend» Google-Maps
Lungenkrebszentrum Helios Klinikum Erfurt
Nordhäuser Straße 74
99089 Erfurt
(Thüringen)
DeutschlandRekrutierend» Google-Maps
Universitaetsklinikum Essen, Apotheke
45147 Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Universitatsklinikum Regensburg Studienburo Dermatologie
93053 Regensburg
(Bayern)
GermanyRekrutierend» Google-Maps
University of California San Diego
92093 La Jolla
United StatesRekrutierend» Google-Maps
University of California, San Francisco
94158-3214 San Francisco
United StatesRekrutierend» Google-Maps
John Wayne Cancer Institute - Saint John's Health Center
90404-2312 Santa Monica
United StatesRekrutierend» Google-Maps
The Melanoma And Skin Cancer Institute
80113 Englewood
United StatesRekrutierend» Google-Maps
Orlando Health Cancer Institute
32806 Orlando
United StatesRekrutierend» Google-Maps
Northwestern Medical Group
60611 Chicago
United StatesRekrutierend» Google-Maps
Massachusetts General Cancer Center
02114 Boston
United StatesRekrutierend» Google-Maps
Rutgers Cancer Institute of New Jersey
08901 New Brunswick
United StatesRekrutierend» Google-Maps
Columbia University Medical Center
10032 New York
United StatesRekrutierend» Google-Maps
University of Rochester
14642 Rochester
United StatesRekrutierend» Google-Maps
Lineberger Comprehensive Cancer Center
27599 Chapel Hill
United StatesRekrutierend» Google-Maps
Duke University Medical Center
27710 Durham
United StatesRekrutierend» Google-Maps
University Hospitals Cleveland Medical Center
44106 Cleveland
United StatesRekrutierend» Google-Maps
Cleveland Clinic Foundation
44195 Cleveland
United StatesRekrutierend» Google-Maps
Thomas Jefferson University Hospital
19107 Philadelphia
United StatesRekrutierend» Google-Maps
University of Tennessee Medical Center
37920 Knoxville
United StatesRekrutierend» Google-Maps
SCRI Partners - Verdi Oncology
37203 Nashville
United StatesRekrutierend» Google-Maps
The University of Texas Southwestern Medical Center
75390 Dallas
United StatesRekrutierend» Google-Maps
Intermountain Medical Center
84107 Murray
United StatesRekrutierend» Google-Maps
University of Virginia Health System
22908 Charlottesville
United StatesRekrutierend» Google-Maps
Virginia Cancer Specialist Research Institute
22031 Fairfax
United StatesZurückgezogen» Google-Maps
Fundacion CENIT para la investigacion en Neurociencias
C1125ABD Ciudad Autonoma
ArgentinaRekrutierend» Google-Maps
DIABAID - Instituto de Asistencia Integral en Diabetes
Ciudad Autonoma
ArgentinaRekrutierend» Google-Maps
Instituto de Oncologia de Rosario - Departamento de Investigaciones
S2000KZE Rosario
ArgentinaRekrutierend» Google-Maps
Centro Medico San Roque
4000 San Miguel de Tucumán
ArgentinaRekrutierend» Google-Maps
Liverpool Hospital (Cancer Therapy Pharmacy)
2170 Liverpool
AustraliaRekrutierend» Google-Maps
Calvary North Adelaid Hospital (HPS Pharmacies)
5006 Adelaide
AustraliaRekrutierend» Google-Maps
Flinders Medical Centre
5042 Bedford Park
AustraliaRekrutierend» Google-Maps
Andrew Love Cancer Centre, University Hospital Geelong
3220 Geelong
AustraliaRekrutierend» Google-Maps
VITAZ vzw - pharm Sara Van Opdenbosch t.a.v. apotheek
9100 Sint Niklaas
BelgiumRekrutierend» Google-Maps
Cliniques Universitaires Saint-Luc
1200 Brussels
BelgiumRekrutierend» Google-Maps
Centro Avancado de Tratamento Oncologico (CENANTRON)
30130-090 Belo Horizonte
BrazilRekrutierend» Google-Maps
Hospital Erasto Gaertner
81520-060 Curitiba
BrazilRekrutierend» Google-Maps
INCA - Brazilian National Cancer Institute
20220-410 Santo Cristo
BrazilRekrutierend» Google-Maps
ONCOSITE - CENTRO DE PESQUISA CLINICA EM ONCOLOGIA LTDA Setor Farmacia Pesquisa Clini
98700-000 Ijui
BrazilRekrutierend» Google-Maps
Hospital Sao Vicente de Paulo - Instituto do Cancer
99010-080 Passo Fundo
BrazilRekrutierend» Google-Maps
Associacao Hospitalar Moinhos de Vento, Centro de Pesquisa Clinica
90035-001 Porto Alegre
BrazilRekrutierend» Google-Maps
Hospital de Clinicas de Porto Alegre - UPCO- pesquisa Clinica em Oncologia do HCPA
90035-903 Porto Alegre
BrazilRekrutierend» Google-Maps
CPO - Centro de Pesquisas em Oncologia
90610-000 Porto Alegre
BrazilRekrutierend» Google-Maps
Clinica de Neoplasias Litoral
88301-220 Itajai
BrazilRekrutierend» Google-Maps
Instituto Joinvilense de Hematologia e Oncologia
89201-260 Joinville
BrazilRekrutierend» Google-Maps
Animi Unidade de Tratamento Oncologico Ltda
88501-001 Lages
BrazilRekrutierend» Google-Maps
Instituto de Ensino e Pesquisas Sao Lucas - IEP HEMOMED
01236-030 Sao Paulo
BrazilRekrutierend» Google-Maps
Fundacao Pio XII - Hospital de Cancer de Barretos
14784-400 Barretos
BrazilRekrutierend» Google-Maps
Nucleo de Pesquisa da Rede Sao Camilo (Instituto Brasileiro de Controle do Cancer)
14784-400 Sao Paulo
BrazilRekrutierend» Google-Maps
Dr. Everett Chalmers Hospital
E3B5N5 Fredericton
CanadaRekrutierend» Google-Maps
Royal Victoria Regional Health Centre
L4M 6M2 Barrie
CanadaRekrutierend» Google-Maps
Sunnybrook Research Institute
M4N 3M5 Toronto
CanadaRekrutierend» Google-Maps
University Health Network, Princess Margaret Cancer Centre
M5G 2C1 Toronto
CanadaRekrutierend» Google-Maps
Universidad Mayor - Centro Oncologia de Precision (PROFAR)
7560907 Santiago
ChileRekrutierend» Google-Maps
Clinica UC San Carlos de Apoquindo
7620002 Santiago
ChileRekrutierend» Google-Maps
University Hospital Hradec Kralove
50005 Hradec Kralove
CzechiaRekrutierend» Google-Maps
University Hospital Ostrava Pharmacy
70852 Ostrava
CzechiaRekrutierend» Google-Maps
Masaryk Memorial Cancer Institute, Hospital Pharmacy
65653 Brno
CzechiaRekrutierend» Google-Maps
CHU de DIJON - Pharmacie Essais Cliniques
21000 Dijon
FranceRekrutierend» Google-Maps
Centre Georges Francois Leclerc
21079 Dijon
FranceRekrutierend» Google-Maps
Institut Claudius Regaud - Pharmacie
31059 Toulouse
FranceRekrutierend» Google-Maps
Gustave Roussy - Pharmacie Essais Cliniques -1
94805 Vaillant
FranceRekrutierend» Google-Maps
Hopital Saint Louis - APHP, Service de Pharmacie - Niveau
75010 Paris
FranceRekrutierend» Google-Maps
Hopital Saint Andre, Pharmacie
33075 Bordeaux
FranceRekrutierend» Google-Maps
Unite de Pharmacie Clinique Oncologique (UPCO)
34090 Montpellier
FranceRekrutierend» Google-Maps
Hopital Ambroise Pare
92100 Boulogne Billancourt
FranceRekrutierend» Google-Maps
CHU HENRI MONDOR Pharmacie Secteur ESSAIS CLINIQUES
94000 Creteil
FranceRekrutierend» Google-Maps
Sainte Catherine Institut du Cancer Avignon Provence
84918 Avignon
FranceRekrutierend» Google-Maps
CHU G. Montpied, Pharmacie, secteur recherche clinique
63003 Clermont-Ferrand
FranceRekrutierend» Google-Maps
CH Le Mans - CCS Pharmacie-essais cliniques, aile B
72037 Le Mans
FranceRekrutierend» Google-Maps
Hopital Avicenne Service Pharmacie Secteur essais cliniques
93000 Bobigny
FranceRekrutierend» Google-Maps
Centre Hospitalier Universitaire de Nice,Hopital l Archet
06200 Nice
FranceRekrutierend» Google-Maps
LTD Cancer Center of Adjara Autonomic Republic
6000 Batumi
GeorgiaRekrutierend» Google-Maps
Israeli Georgian medical research clinic Helsicore
0112 T'bilisi
GeorgiaRekrutierend» Google-Maps
LTD Research Institute of Clinical Medicine (LLC Todua Clinic)
0112 T'bilisi
GeorgiaRekrutierend» Google-Maps
High Technology Medical Center, University Clinic Tbilisi
0144 T'bilisi
GeorgiaRekrutierend» Google-Maps
Tbilisi Institute of Medicine (TIM)
0168 T'bilisi
GeorgiaRekrutierend» Google-Maps
JSC K. Eristavi National Center of Experimental and Clinical Surgery
0159 Tbilisi
GeorgiaRekrutierend» Google-Maps
A Oncology Dpt, Laiko General Hospital of Athens
11527 Goudi
GreeceRekrutierend» Google-Maps
A Oncology Dpt, Metropolitan Hospital
18547 Athens
GreeceRekrutierend» Google-Maps
Bioclinic of Thessaloniki
54622 Thessaloniki
GreeceRekrutierend» Google-Maps
Iatriko Diavalkaniko Thessaloniki, Pharmacy
57001 Thessaloniki
GreeceRekrutierend» Google-Maps
University Hospital Galway
H91 YR71 Galway
IrelandRekrutierend» Google-Maps
University College Cork-Cork University Maternity Hospital
Cork
IrelandRekrutierend» Google-Maps
St Vincent's University Hospital
D04 T6F4 Dublin
IrelandRekrutierend» Google-Maps
The Chaim Sheba Medical Center
52621 Ramat-Gan
IsraelRekrutierend» Google-Maps
Hadassah Ein Kerem Medical Center
91120 Jerusalem
IsraelRekrutierend» Google-Maps
UOC del Farmaco - PO San Salvatore
67100 L'Aquila
ItalyRekrutierend» Google-Maps
Universita della Campania Luigi Vanvitella
80121 Napoli
ItalyRekrutierend» Google-Maps
Instituto Nazionale Tumori IRCCS Fondazione G. Pascale
80131 Napoli
ItalyRekrutierend» Google-Maps
Clinica Malattie Infettive, Azienda Ospedaliero Universitaria
33100 Udine
ItalyRekrutierend» Google-Maps
Fondazione Policlinico Campus Bio-Medico
00128 Rome
ItalyRekrutierend» Google-Maps
Farmacia Ospedaliera, Fondazione Policlinico Universitario Agostini Gemeli IRCCS
00168 Rome
ItalyRekrutierend» Google-Maps
Farmacia Ospedaliera, Instituto Europeo di Oncologia
20141 Milan
ItalyRekrutierend» Google-Maps
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Tumori Giovanni Paolo II - Ospedale Oncologico di Bari
70124 Bari
ItalyRekrutierend» Google-Maps
Istituto Di Ricovero E Cura A Carattere Scientifico (Ircss)
00167 Roma
ItalyRekrutierend» Google-Maps
Arcispedale SantAnna UOC Farmacia Ospedaliera Ufficio sperimentazioni cliniche, SETTORE 2B1 Presidi
44124 Cona
ItalyRekrutierend» Google-Maps
Azienda Ospedaliero Universitaria Maggiore della Carita, Farmacia Ospedaliera
28100 Novara
ItalyRekrutierend» Google-Maps
Farmacia Ospedaliera - Azienda Ospedaliero Universitaria delle Marche
60126 Torrette
ItalyRekrutierend» Google-Maps
Ospedale S.Chiara - APSS di Trento - Magazzino Farmacia
38123 Trento
ItalyRekrutierend» Google-Maps
Preparaciones Oncologicas S. C.
37178 Leon Guanajuato
MexicoRekrutierend» Google-Maps
Hospital Civil de Guadalajara Fray Antonio Alcalde
44280 Guadalajara
MexicoRekrutierend» Google-Maps
Investigacion Biomedica para el Desarrollo de Farmacos S.A de C.V
45070 Zapopan
MexicoRekrutierend» Google-Maps
iCan Oncology Center S.A de C.V.
64710 Monterrey
MexicoRekrutierend» Google-Maps
Neurociencias Estudios Clinicos S. C.
80020 Culiacan
MexicoRekrutierend» Google-Maps
Centro de Atencion e Investigacion Clinica en Oncologia
97134 Merida
MexicoRekrutierend» Google-Maps
Mazowiecki Szpital Wojewodzki, Siedleckie Centrum Onkologii
08-110 Siedlce
PolandRekrutierend» Google-Maps
Uniwersyteckie Centrum Kliniczne (UCK)
80-214 Gdansk
PolandRekrutierend» Google-Maps
Wojewodzki Szpital Specjalistyczny im. J. Korczaka w Slupsku
16-200 Slupsk
PolandRekrutierend» Google-Maps
Centrul de Oncologie Sf. Nectarie S.R.L/SC
200542 Craiova
RomaniaRekrutierend» Google-Maps
Centrul De Oncologie Euroclinic
700106 Iași
RomaniaRekrutierend» Google-Maps
Oncocenter-Oncologie Clinica SRL
300210 Timisoara
RomaniaRekrutierend» Google-Maps
Institul Oncologic Prof. Dr Ion Chiricuta
400015 Cluj Napoca
RomaniaRekrutierend» Google-Maps
Institute of Oncology Bucharest
022328 Bucharest
RomaniaRekrutierend» Google-Maps
The Medical Oncology Centre of Rosebank
2196 Johannesburg
South AfricaRekrutierend» Google-Maps
Wilgers Oncology Center
7570 Pretoria
South AfricaRekrutierend» Google-Maps
Cape Gate Oncology Trials
7570 Cape Town
South AfricaRekrutierend» Google-Maps
Hospital Universitario Virgen Macarena
41009 Sevilla
SpainRekrutierend» Google-Maps
Hospital Universitario Central de Asturias
33011 Oviedo
SpainRekrutierend» Google-Maps
Hospital Universitario Marques De Valdecilla
39008 Santander
SpainRekrutierend» Google-Maps
Hospital Universitario Quiron Dexeus Barcelona
08028 Barcelona
SpainRekrutierend» Google-Maps
Area dassajos clinics/Medicaments en investigacio, Servei de Farmacia Hospital Clinic de Barcelona (ICMHO)
08035 Barcelona
SpainRekrutierend» Google-Maps
Hospital Universitario Vall d'Hebron, Edificio General-Planta Baja, UITM, Unidad de Farmacia de Ensa
08035 Barcelona
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen de las Nieves
18014 Granada
SpainRekrutierend» Google-Maps
Hospital Universitario Lucus Augusti
27003 Lugo
SpainRekrutierend» Google-Maps
Hospital General Universitario Gregorio Maranon (HGUGM)
28007 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario HM Sanchinarro
28050 Madrid
SpainRekrutierend» Google-Maps
Fundacion Instituto Valenciano de Oncologia
46009 Valencia
SpainRekrutierend» Google-Maps
Hospital Clinico Universitario de Valencia
46010 Valencia
SpainRekrutierend» Google-Maps
Sbu Dr. A.Y. Ankara Onkoloji Suam
06100 Ankara
TurkeyRekrutierend» Google-Maps
Gulhane Egitim ve Arastirma Hastanesi
06010 Keçiören
TurkeyRekrutierend» Google-Maps
Adana Kisla Baskent Unv Hospital
01120 Adana
TurkeyRekrutierend» Google-Maps
Dicle University, Faculty of Medicine
21280 Diyarbakir
TurkeyRekrutierend» Google-Maps
Trakya Universitesi, Balkan Onkoloji Hastanesi Linik Arastirmar Odasi
22130 Iskender
TurkeyRekrutierend» Google-Maps
Medical Park Gaziantep Hastanesi
27310 Sehitkamil
TurkeyRekrutierend» Google-Maps
Goztepe Prof. Dr. Suleyman Yalcin City Hospital
81450 Istanbul
TurkeyRekrutierend» Google-Maps
Istanbul Universitesi CerrahpaSa- Cerrahpasa Tip Fakultesi
34098 Fatih
TurkeyRekrutierend» Google-Maps
Izmir Katip Celebi University Ataturk training and Research Hospital
35360 Izmir
TurkeyRekrutierend» Google-Maps
Royal Devon University Healthcare NHS Foundation Trust, Clinical Trials Pharmacy
EX2 5DW Exeter
United KingdomRekrutierend» Google-Maps
Clinical research pharmacy
SW3 6JJ Chelsea
United KingdomRekrutierend» Google-Maps
Pharmacy Clinical Trials, Pharmacy Department, Alexander Donald Building, Western General Hospital
EH4 2LF Edinburgh
United KingdomRekrutierend» Google-Maps
Clinical Trials Unit Bristol Haematology & Oncology Centre
BS2 8ED Bristol
United KingdomRekrutierend» Google-Maps
Musgrove Park Hospital, Somerset Foundation Trust
TA1 5DA Taunton
United KingdomRekrutierend» Google-Maps
Pharmacy Chemotherapy Unit, St Barthomews Hospital West Smithfield
EC1A 7BE London
United KingdomRekrutierend» Google-Maps
The Christie NHS Foundation Trust
M20 4BX Manchester
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This study is researching an experimental drug called REGN3767, also known as fianlimab

(R3767), when combined with another medication called cemiplimab (each individually called a

"study drug" or called "study drugs" when combined) compared with an approved medication

called pembrolizumab.

The objective of this study is to see if the combination of fianlimab and cemiplimab is an

effective treatment compared to pembrolizumab in patients that have had melanoma removal

surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an

approved treatment in some countries in this clinical setting.

The study is looking at several other research questions, including:

- What side effects may happen from receiving the study drugs.

- How much study drug is in the blood at different times.

- Whether the body makes antibodies against the study drug (which could make the drug less

effective or could lead to side effects). Antibodies are proteins that are naturally

found in the blood stream that fight infections.

- How administering the study drugs might improve quality of life.

Ein-/Ausschlusskriterien

Key Inclusion Criteria:

1. All patients must be either stage IIB, IIC, III, or stage IV per American Joint

Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that

is completely surgically resected in order to be eligible as defined by the protocol

2. Complete surgical resection must be performed within 12 weeks prior to randomization,

and enrollment may occur only after satisfactory wound healing from the surgery

3. All patients must have disease-free status documented by a complete physical

examination and imaging studies within 4 weeks prior to randomization, as described in

the protocol

Key Exclusion Criteria:

1. Uveal melanoma

2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.

3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune

disease that required treatment

4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus

(HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is

related to, or results in chronic infection, as described in the protocol

5. Another malignancy that is currently progressing or that required active treatment in

the past 5 years, as described in the protocol

6. Participants with a history of myocarditis

7. Adolescent patients (≥12 to <18 years old) with body weight <40 kg

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Studien-Rationale

Primary outcome:

1. Relapse free survival (RSF) (Time Frame - Up to 5 Years):
Time from randomization to the first documented recurrence of disease at any site (excluding new primary melanomas) or death from any cause, whichever occurs first.



Secondary outcome:

1. Distant metastasis-free survival (DMFS) (Time Frame - Up to 5 Years):
Time between the date of randomization and the date of the first distant metastasis.

2. Overall survival (OS) (Time Frame - Up to 5 Years):
Time from randomization to the date of death.

3. Occurrence of treatment-emergent adverse events (TEAEs) (Time Frame - Up to 5 Years):
A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

4. Occurrence of immune-mediated EAEs (im-EAEs) (Time Frame - Up to 5 Years):
imAEs are a unique set of toxicities thought to be caused by unrestrained cellular immune responses.

5. Occurrence of serious adverse events (SAEs) (Time Frame - Up to 5 Years):
An SAE is any untoward medical occurrence that at any dose: Results in death - includes all deaths, even those that appear to be completely unrelated to study drug (eg, a car accident in which a patient is a passenger). Is life-threatening Requires in-patient hospitalization or prolongation of existing hospitalization. Results in persistent or significant disability/incapacity Is a congenital anomaly/birth defect. Is an important medical event

6. Occurrence of adverse events of special interest (AESIs) (Time Frame - Up to 5 Years):
An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate. Such an event might warrant further investigation in order to characterize and understand it

7. Occurrence of TEAEs resulting in death (Time Frame - Up to 5 Years):
A TEAE resulting in death is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

8. Occurrence of dose-limiting toxicity (DLT) (Time Frame - Up to 5 Years):
A DLT is defined as a study-drug related TEAE, including imAEs, that could preclude enrolling additional adolescent patients at the selected dose. Dose-limiting toxicity will be evaluated in adolescents only.

9. Occurrence of interruption or discontinuation of study drug(s) due to TEAE (Time Frame - Up to 5 Years):
A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.

10. Occurrence of laboratory abnormalities (Time Frame - Up to 5 Years):
As assessed by the NCI-CTCAE grading system (≥ Grade 3 or higher)

11. Concentrations of fianlimab in serum over time (Time Frame - Up to 5 Years):
The concentrations of fianlimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

12. Concentrations of cemiplimab in serum over time (Time Frame - Up to 5 Years):
The concentrations of cemiplimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.

13. Concentration of finalimab anti-drug antibodies (ADA) and neutralizing antibodies (Time Frame - Up to 5 Years):
Immunogenicity will be characterized per drug molecule by ADA and NAb status.

14. Concentration of cemiplimab anti-drug antibodies (ADA) and neutralizing antibodies (Time Frame - Up to 5 Years):
Immunogenicity will be characterized per drug molecule by ADA and NAb status.

15. Patient report outcomes (PRO) for adults as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30) (Time Frame - Up to 5 Year):
The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome. The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. More points are considered to have a better outcome.

16. PRO for adults as measured by the European Quality of Life Dimension 5 (EQ-5D-5L) (Time Frame - Up to 5 Years):
The EQ-5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

17. PRO for adults as measured by the Functional Assessment of Cancer Therapy (FACT) - melanoma (Time Frame - Up to 5 Years):
The FACT-M is a melanoma-specific quality of life questionnaire that is composed of items from the Functional Assessment of Cancer Therapy-General (FACT-G). The FACT-M is scored on a 5 point Likert-scale: "Not at all", "A little bit", "Somewhat", "Quite a bit", and "Very much.". A Higher score represents higher Health Related Quality of Life (HRQoL).

18. PRO for adults as determined by the Patient Global Impressions Scale (PGIS) (Time Frame - Up to 5 Years):
The PGIS is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time by using a 4-point Likert scale that ranges from (1) = "none (no symptoms)" to (4) = "severe".

19. PRO for adults as determined by the Patient Global Impressions of Change Scale (PGIC) (Time Frame - Up to 5 Years):
The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 5-point Likert scale anchored by (1) "much better" to (5) "much worse", with (4) = "no change".

20. Time to global health status/quality of life deterioration per EORTC QLQ-C30 (Time Frame - Up to 5 years)

21. Time to physical functioning deterioration per EORTC QLQ-C30 (Time Frame - Up to 5 Years)

22. Time to role functioning deterioration per EORTC QLQ-C30 (Time Frame - Up to 5 Years)

Studien-Arme

  • Experimental: Fianlimab HD + Cemiplimab
    Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab
  • Experimental: Fianlimab LD + Cemiplimab
    Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab
  • Active Comparator: Pembrolizumab
    Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo

Geprüfte Regime

  • Fianlimab (REGN3767):
    Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
  • Cemiplimab (REGN2810 / Libtayo / ):
    Cemiplimab will be administered by IV infusion Q 3 weeks
  • Pembrolizumab (MK-3475 / lambrolizumab / Keytruda / ):
    Pembrolizumab will be administered by IV infusion Q 3 weeks
  • Placebo:
    Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.